Dongguan HEC Biopharmaceutical

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
GLP-1 receptor; FGF21 receptorProtein / enzyme therapeutic
ObesityType 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.